Zentalis Pharmaceuticals (NASDAQ:ZNTL) Lowered to “Neutral” at UBS Group

Zentalis Pharmaceuticals (NASDAQ:ZNTL) was downgraded by investment analysts at UBS Group from a “buy” rating to a “neutral” rating in a research report issued on Thursday, Briefing.com reports. They presently have a $5.00 price objective on the stock, down from their previous price objective of $28.00. UBS Group’s price target indicates a potential upside of 20.77% from the company’s previous close.

Other equities analysts have also recently issued research reports about the company. Wells Fargo & Company cut Zentalis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $29.00 to $9.00 in a research note on Tuesday. Stifel Nicolaus lowered their price objective on Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday. Morgan Stanley reissued an “equal weight” rating and set a $8.00 target price (down previously from $38.00) on shares of Zentalis Pharmaceuticals in a research report on Tuesday. HC Wainwright lowered their price target on Zentalis Pharmaceuticals from $40.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday. Finally, Wedbush cut shares of Zentalis Pharmaceuticals from a “neutral” rating to an “underperform” rating and cut their price objective for the stock from $15.00 to $4.00 in a report on Tuesday. One research analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $11.33.

Zentalis Pharmaceuticals Stock Down 50.7 %

Shares of Zentalis Pharmaceuticals stock opened at $4.14 on Thursday. The firm has a market cap of $294.06 million, a PE ratio of -1.24 and a beta of 1.83. Zentalis Pharmaceuticals has a 52 week low of $3.93 and a 52 week high of $30.53. The business’s fifty day simple moving average is $11.53 and its 200-day simple moving average is $13.08.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Tuesday, May 7th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.91. The company had revenue of $40.56 million during the quarter, compared to analyst estimates of $35.00 million. During the same quarter last year, the business posted ($1.07) EPS. As a group, equities analysts expect that Zentalis Pharmaceuticals will post -2.72 earnings per share for the current year.

Insider Activity at Zentalis Pharmaceuticals

In related news, CFO Cam Gallagher sold 9,597 shares of the firm’s stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $11.98, for a total transaction of $114,972.06. Following the sale, the chief financial officer now owns 633,680 shares in the company, valued at $7,591,486.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Zentalis Pharmaceuticals news, insider Diana Hausman sold 3,356 shares of the firm’s stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $12.62, for a total value of $42,352.72. Following the transaction, the insider now directly owns 373,876 shares of the company’s stock, valued at $4,718,315.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Cam Gallagher sold 9,597 shares of the business’s stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $11.98, for a total value of $114,972.06. Following the transaction, the chief financial officer now directly owns 633,680 shares in the company, valued at $7,591,486.40. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quest Partners LLC purchased a new position in Zentalis Pharmaceuticals in the fourth quarter valued at about $38,000. Tower Research Capital LLC TRC raised its position in shares of Zentalis Pharmaceuticals by 252.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company’s stock valued at $55,000 after purchasing an additional 2,589 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Zentalis Pharmaceuticals by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 5,989 shares of the company’s stock valued at $91,000 after buying an additional 1,519 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Zentalis Pharmaceuticals by 352.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,188 shares of the company’s stock worth $124,000 after buying an additional 6,379 shares in the last quarter. Finally, OneAscent Financial Services LLC bought a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter worth $156,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.